Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy
Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline ha...
Gespeichert in:
Veröffentlicht in: | Journal of cardiology 2010-03, Vol.55 (2), p.174-179 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 179 |
---|---|
container_issue | 2 |
container_start_page | 174 |
container_title | Journal of cardiology |
container_volume | 55 |
creator | Kinbara, Terufumi, MD Hayano, Tomoko, MD Ohtani, Nozomu, MD Furutani, Yuhji, MD Moritani, Kohshiro, MD Matsuzaki, Masunori, MD, FJCC |
description | Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. Methods and results Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n = 15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 ± 0.36 to 0.67 ± 0.16 mg/dl ( p < 0.01), and Ccr significantly increased from 62.4 ± 15.6 to 80.4 ± 8.39 ml/min ( p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 ± 0.21 to 1.28 ± 0.21 mg/dl ( p < 0.01), and Ccr significantly decreased from 63.7 ± 16.1 to 46.1 ± 10.6 ml/min ( p < 0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 ± 0.58 to 1.71 ± 0.38 mg/dl ( p < 0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 ± 31.0 to 239 ± 34 μg/ml ( p < 0.01). Conclusions These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN. |
doi_str_mv | 10.1016/j.jjcc.2009.10.006 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_748991220</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0914508709002809</els_id><sourcerecordid>748991220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-31810c305795424d34f74e45c048cbc1515173f21a15fe1a0c02f0c12167a1e03</originalsourceid><addsrcrecordid>eNp9kU-L1TAUxYMoznOcL-BCunPV502aNg2IIMP4BwZdqItZhcztrS-1L6lJO9Bvb8obXcxiyCLhcM6B_A5jrzjsOfDm7bAfBsS9ANBZ2AM0T9iOt6opparap2wHmsuyhladsRcpDdkAum2eszMBIr8bvWM3V33v0OJahL74WlqkeR1xTTM5T4X1XWGPzofpsI7jpjhfTJHuyM_O_yow-DnaNJfOdwtSV3iaDjFMdj6sL9mz3o6JLu7vc_bz49WPy8_l9bdPXy4_XJdYq2ouK95ywApqpWspZFfJXkmSNYJs8RZ5nY-qesEtr3viFhBED8gFb5TlBNU5e3PqnWL4s1CazdElpHG0nsKSjJKt1lyIzSlOTowhpUi9maI72rgaDmYjagazETUb0U3LwHLo9X39cnuk7n_kH8JseHcyUP7knaNoEjrymYaLhLPpgnu8__2DOGbQeZLxN62UhrBEn_EZbpIwYL5vm26TggYQLejqL6Z3m_4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>748991220</pqid></control><display><type>article</type><title>Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kinbara, Terufumi, MD ; Hayano, Tomoko, MD ; Ohtani, Nozomu, MD ; Furutani, Yuhji, MD ; Moritani, Kohshiro, MD ; Matsuzaki, Masunori, MD, FJCC</creator><creatorcontrib>Kinbara, Terufumi, MD ; Hayano, Tomoko, MD ; Ohtani, Nozomu, MD ; Furutani, Yuhji, MD ; Moritani, Kohshiro, MD ; Matsuzaki, Masunori, MD, FJCC</creatorcontrib><description><![CDATA[Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. Methods and results Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n = 15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 ± 0.36 to 0.67 ± 0.16 mg/dl ( p < 0.01), and Ccr significantly increased from 62.4 ± 15.6 to 80.4 ± 8.39 ml/min ( p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 ± 0.21 to 1.28 ± 0.21 mg/dl ( p < 0.01), and Ccr significantly decreased from 63.7 ± 16.1 to 46.1 ± 10.6 ml/min ( p < 0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 ± 0.58 to 1.71 ± 0.38 mg/dl ( p < 0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 ± 31.0 to 239 ± 34 μg/ml ( p < 0.01). Conclusions These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.]]></description><identifier>ISSN: 0914-5087</identifier><identifier>EISSN: 1876-4738</identifier><identifier>DOI: 10.1016/j.jjcc.2009.10.006</identifier><identifier>PMID: 20206069</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acetylcysteine - administration & dosage ; Acetylcysteine - therapeutic use ; Aged ; Aminophylline ; Aminophylline - administration & dosage ; Aminophylline - therapeutic use ; Angioplasty, Balloon, Coronary - adverse effects ; beta 2-Microglobulin - blood ; beta 2-Microglobulin - urine ; Cardiovascular ; Contrast Media - adverse effects ; Contrast-induced nephropathy ; Coronary Angiography - adverse effects ; Creatinine - blood ; Creatinine - metabolism ; Female ; Humans ; Kidney Diseases - chemically induced ; Kidney Diseases - prevention & control ; Male ; N-acetylcysteine ; Renal function</subject><ispartof>Journal of cardiology, 2010-03, Vol.55 (2), p.174-179</ispartof><rights>Japanese College of Cardiology</rights><rights>2009 Japanese College of Cardiology</rights><rights>Copyright 2009 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-31810c305795424d34f74e45c048cbc1515173f21a15fe1a0c02f0c12167a1e03</citedby><cites>FETCH-LOGICAL-c573t-31810c305795424d34f74e45c048cbc1515173f21a15fe1a0c02f0c12167a1e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0914508709002809$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20206069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kinbara, Terufumi, MD</creatorcontrib><creatorcontrib>Hayano, Tomoko, MD</creatorcontrib><creatorcontrib>Ohtani, Nozomu, MD</creatorcontrib><creatorcontrib>Furutani, Yuhji, MD</creatorcontrib><creatorcontrib>Moritani, Kohshiro, MD</creatorcontrib><creatorcontrib>Matsuzaki, Masunori, MD, FJCC</creatorcontrib><title>Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy</title><title>Journal of cardiology</title><addtitle>J Cardiol</addtitle><description><![CDATA[Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. Methods and results Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n = 15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 ± 0.36 to 0.67 ± 0.16 mg/dl ( p < 0.01), and Ccr significantly increased from 62.4 ± 15.6 to 80.4 ± 8.39 ml/min ( p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 ± 0.21 to 1.28 ± 0.21 mg/dl ( p < 0.01), and Ccr significantly decreased from 63.7 ± 16.1 to 46.1 ± 10.6 ml/min ( p < 0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 ± 0.58 to 1.71 ± 0.38 mg/dl ( p < 0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 ± 31.0 to 239 ± 34 μg/ml ( p < 0.01). Conclusions These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.]]></description><subject>Acetylcysteine - administration & dosage</subject><subject>Acetylcysteine - therapeutic use</subject><subject>Aged</subject><subject>Aminophylline</subject><subject>Aminophylline - administration & dosage</subject><subject>Aminophylline - therapeutic use</subject><subject>Angioplasty, Balloon, Coronary - adverse effects</subject><subject>beta 2-Microglobulin - blood</subject><subject>beta 2-Microglobulin - urine</subject><subject>Cardiovascular</subject><subject>Contrast Media - adverse effects</subject><subject>Contrast-induced nephropathy</subject><subject>Coronary Angiography - adverse effects</subject><subject>Creatinine - blood</subject><subject>Creatinine - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney Diseases - chemically induced</subject><subject>Kidney Diseases - prevention & control</subject><subject>Male</subject><subject>N-acetylcysteine</subject><subject>Renal function</subject><issn>0914-5087</issn><issn>1876-4738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-L1TAUxYMoznOcL-BCunPV502aNg2IIMP4BwZdqItZhcztrS-1L6lJO9Bvb8obXcxiyCLhcM6B_A5jrzjsOfDm7bAfBsS9ANBZ2AM0T9iOt6opparap2wHmsuyhladsRcpDdkAum2eszMBIr8bvWM3V33v0OJahL74WlqkeR1xTTM5T4X1XWGPzofpsI7jpjhfTJHuyM_O_yow-DnaNJfOdwtSV3iaDjFMdj6sL9mz3o6JLu7vc_bz49WPy8_l9bdPXy4_XJdYq2ouK95ywApqpWspZFfJXkmSNYJs8RZ5nY-qesEtr3viFhBED8gFb5TlBNU5e3PqnWL4s1CazdElpHG0nsKSjJKt1lyIzSlOTowhpUi9maI72rgaDmYjagazETUb0U3LwHLo9X39cnuk7n_kH8JseHcyUP7knaNoEjrymYaLhLPpgnu8__2DOGbQeZLxN62UhrBEn_EZbpIwYL5vm26TggYQLejqL6Z3m_4</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Kinbara, Terufumi, MD</creator><creator>Hayano, Tomoko, MD</creator><creator>Ohtani, Nozomu, MD</creator><creator>Furutani, Yuhji, MD</creator><creator>Moritani, Kohshiro, MD</creator><creator>Matsuzaki, Masunori, MD, FJCC</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy</title><author>Kinbara, Terufumi, MD ; Hayano, Tomoko, MD ; Ohtani, Nozomu, MD ; Furutani, Yuhji, MD ; Moritani, Kohshiro, MD ; Matsuzaki, Masunori, MD, FJCC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-31810c305795424d34f74e45c048cbc1515173f21a15fe1a0c02f0c12167a1e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acetylcysteine - administration & dosage</topic><topic>Acetylcysteine - therapeutic use</topic><topic>Aged</topic><topic>Aminophylline</topic><topic>Aminophylline - administration & dosage</topic><topic>Aminophylline - therapeutic use</topic><topic>Angioplasty, Balloon, Coronary - adverse effects</topic><topic>beta 2-Microglobulin - blood</topic><topic>beta 2-Microglobulin - urine</topic><topic>Cardiovascular</topic><topic>Contrast Media - adverse effects</topic><topic>Contrast-induced nephropathy</topic><topic>Coronary Angiography - adverse effects</topic><topic>Creatinine - blood</topic><topic>Creatinine - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney Diseases - chemically induced</topic><topic>Kidney Diseases - prevention & control</topic><topic>Male</topic><topic>N-acetylcysteine</topic><topic>Renal function</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kinbara, Terufumi, MD</creatorcontrib><creatorcontrib>Hayano, Tomoko, MD</creatorcontrib><creatorcontrib>Ohtani, Nozomu, MD</creatorcontrib><creatorcontrib>Furutani, Yuhji, MD</creatorcontrib><creatorcontrib>Moritani, Kohshiro, MD</creatorcontrib><creatorcontrib>Matsuzaki, Masunori, MD, FJCC</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kinbara, Terufumi, MD</au><au>Hayano, Tomoko, MD</au><au>Ohtani, Nozomu, MD</au><au>Furutani, Yuhji, MD</au><au>Moritani, Kohshiro, MD</au><au>Matsuzaki, Masunori, MD, FJCC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy</atitle><jtitle>Journal of cardiology</jtitle><addtitle>J Cardiol</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>55</volume><issue>2</issue><spage>174</spage><epage>179</epage><pages>174-179</pages><issn>0914-5087</issn><eissn>1876-4738</eissn><abstract><![CDATA[Summary Background Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN. Methods and results Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n = 15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 ± 0.36 to 0.67 ± 0.16 mg/dl ( p < 0.01), and Ccr significantly increased from 62.4 ± 15.6 to 80.4 ± 8.39 ml/min ( p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 ± 0.21 to 1.28 ± 0.21 mg/dl ( p < 0.01), and Ccr significantly decreased from 63.7 ± 16.1 to 46.1 ± 10.6 ml/min ( p < 0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 ± 0.58 to 1.71 ± 0.38 mg/dl ( p < 0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 ± 31.0 to 239 ± 34 μg/ml ( p < 0.01). Conclusions These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.]]></abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>20206069</pmid><doi>10.1016/j.jjcc.2009.10.006</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0914-5087 |
ispartof | Journal of cardiology, 2010-03, Vol.55 (2), p.174-179 |
issn | 0914-5087 1876-4738 |
language | eng |
recordid | cdi_proquest_miscellaneous_748991220 |
source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Acetylcysteine - administration & dosage Acetylcysteine - therapeutic use Aged Aminophylline Aminophylline - administration & dosage Aminophylline - therapeutic use Angioplasty, Balloon, Coronary - adverse effects beta 2-Microglobulin - blood beta 2-Microglobulin - urine Cardiovascular Contrast Media - adverse effects Contrast-induced nephropathy Coronary Angiography - adverse effects Creatinine - blood Creatinine - metabolism Female Humans Kidney Diseases - chemically induced Kidney Diseases - prevention & control Male N-acetylcysteine Renal function |
title | Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A32%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20N-acetylcysteine%20and%20aminophylline%20in%20preventing%20contrast-induced%20nephropathy&rft.jtitle=Journal%20of%20cardiology&rft.au=Kinbara,%20Terufumi,%20MD&rft.date=2010-03-01&rft.volume=55&rft.issue=2&rft.spage=174&rft.epage=179&rft.pages=174-179&rft.issn=0914-5087&rft.eissn=1876-4738&rft_id=info:doi/10.1016/j.jjcc.2009.10.006&rft_dat=%3Cproquest_cross%3E748991220%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=748991220&rft_id=info:pmid/20206069&rft_els_id=1_s2_0_S0914508709002809&rfr_iscdi=true |